Navigation Links
Health Briefs TV Features SFJ Pharmaceuticals

Coral Springs, FL (PRWEB) September 20, 2013

The producers of Health Briefs TV are pleased to announce that SFJ Pharmaceuticals will be featured in an upcoming segment on "Innovative Drug Development and Clinical Research Driving Improved Patient Care" as part of the show's Medical Minutes series.

Their value of pharmaceuticals is especially evident in the field of oncology, where the speed of development and availability of drugs may offer the first ever treatment, or have significant advantages over existing drugs. With the costs of developing a cancer drug reaching up to one billion dollars, however, many pharmaceutical companies are using a step-by-step approach. They first advance their most promising drugs for one cancer type, line of therapy or stage, and then advance for additional cancer types, lines of therapy or stages, thus delaying the time it takes for life-saving and life-enhancing to get into the hands or physicians and patients.

Additionally, drugs are first developed for the largest markets, like breast and lung cancer. Drugs for other cancer types, like thyroid and kidney, are not as aggressively developed. Years may go by while patients in need wait, without access to life-saving or life-enhancing drugs.

Pleasanton, California-headquartered SFJ Pharmaceuticals has developed a revolutionary model to overcome drug development challenges. The company captures the lost value for pharmaceutical companies and patients, by taking drugs which are proven in one type of cancer, and helping to accelerate them through clinical development for many different types and stages of cancer.

The five-minute Health Briefs TV segment will educate viewers on the importance of efficient drug development, and will feature the innovative model developed by SFJ Pharmaceuticals to make drugs available to more patients, sooner. The segment will highlight several of SFJ's partnerships, including Eisai Pharmaceuticals for Phase III development of their drug, Lenvatinib, to treat 131I-Refractory Differentiated Thyroid Cancer; Pfizer's drug, Dacomitinib, for first-line treatment of non-small cell lung cancer; and Pfizer's drug, Axitinib, for the adjuvant treatment of renal cell carcinoma. For more information about SFJ Pharmaceuticals, please visit

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Bel Marra Health Reports on Recent Research Finding Prolonged Life in Those Who Receive Corrective Eye Surgery
2. Online USA Doctors/Virtual Doctors Creates Comprehensive Female Health Plan That Prevents Premature Death in Postmenopausal Women
3. Diet Doc Hormone Diets & Weight Loss Plans Now Helps Clients Achieve a Healthy Lifestyle and Eliminate Causes of Weight Gain With Exclusive Diet Pills
4. Gorman Health Group Expert to Outline the Components of a Successful Medicare Advantage Risk-Adjustment Program
5. Zion Health Announces Native Remedy; Ancient Clay Soaps for Sensitive Skin; New Addition to Whole Foods Market Body Care in Andover, MA
6. Best Natural Acne Treatment Review Published by Health Company
7. School of Public Health Receives $390,000 Grant to Study Alcohol Use Among Youth Acquiring HIV
8. CHL to Hold Original Thought-Leadership Series about Need for Hispanics in the Healthcare and Biomedical Fields; City of Hope to Host Signature Event on Their Campus
9. CDPHP Health Plans Ranked As Best in New York State
10. Oakwood Medical Avatar Brings Personalized Health Info to Mobile Devices
11. Online USA Doctors Announces a New Online, Medical Record System That Improves Patient Health Outcomes
Post Your Comments:
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from reveals that behind the tendency to set ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their ... Award, an essay contest in which patients and their families pay tribute to a ... the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... National recruitment firm ... life sciences executive with extensive sequencing and genomics experience, as Vice President of North ... Ms. Hill will be responsible for leading the sales team in the commercialization of ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
Breaking Medicine Technology: